The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Cipla's product portfolio spans complex generics as well as drugs in the respiratory anti-retroviral urology cardiolo... In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure ...

while Cancer drug Revlimid sales came in stable, though, with stiff competition, FY26 sales pattern is set to differ for Revlimid. While brokerages in unison sang praises on the Q3 positive earnings ...

Cipla is currently valued at Rs 1480.00, indicating a daily change of 1.09%. The 5-day exponential moving average stands at Rs 1470.50. Cipla is currently trading at Rs 1477.7, reflecting a positive ...

The domestic market saw a 7% rise in sales, driven by gains in cardiac, oncology, and dermatology therapies, even as anti-infective and respiratory drugs underperformed. Nuvama found that Sun Pharma, ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

These U.S. sales are usually driven by tumour drug Lanreotide, Cipla's second-biggest revenue generator. However, the company had warned in October that certain supply chain issues related to the ...

Medical Dialogues team had earlier reported that Cipla Limited had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...